ClinicalTrials.gg
CompletedNCT05720767Updated Mar 1, 2023

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

A Phase 1 interventional study of HMPL-523 and Itraconazole in Relapsed or Refractory Lymphoma, sponsored by Hutchmed. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-01.

Primary conditionLymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hutchmed · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,909 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
971st of 1,594
28 · median 36
Started
2022
with 44 others
Phase 1
581 of 1,909
37 open now
Registered
1,771st of 1,909
by date

Among the 1,909 studies in Lymphoma with a site in United States, this one is the 971st largest by enrollment of the 1,594 interventional ones that give a count, is one of 45 that started in 2022, is one of 581 in phase 1, and was the 1,771st registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,909 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,909 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Read the detailed description

This study will be a single-center, open-label, 2-part, 2-period fixed-sequence crossover study to be conducted with 28 healthy male and female volunteers. The study will consist of a Screening Phase (Screening and Day -1), a Treatment Phase (Period 1 and Period 2), and an End of Study (EOS) Phase.

03

Conditions studied

  • Relapsed or Refractory Lymphoma

Browse trials for

04

In context

Lymphoma Reclassified

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

This study's enrollment of 28 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. The volunteer is male or female between the ages of 18 and 55 years old (inclusive) at the time of .

      1. The volunteer has a (BMI) >18 and ≤29.9 kg/m2 at screening.
      1. Females must be (defined as absence of menses for at least one year without alternative medical cause) or permanently sterile by total hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
      1. Males, including those who have had a successful vasectomy, must use a condom during sexual intercourse with women of , starting from their first dose of study drug through 30 days after their last dose of study drug. Alternatively, abstinence is allowed if it is the normal and preferred lifestyle of the volunteer.
      1. The volunteer must provide written informed consent prior to any study specific screening procedures.
      1. The volunteer is willing and able to comply with all aspects of the protocol, as determined by the PI.
      1. The volunteer must have normal laboratory results for total , (AST), and alanine aminotransferase (ALT); must be > 90 mL/min estimated using the Cockcroft-Gault equation.

Exclusion criteria

Exclusion Criteria:

    1. The volunteer has a known history of any gastrointestinal surgery or any condition possibly affecting drug absorption (eg, cholecystectomy, gastrectomy, achlorhydria, peptic ulcer disease, or history of stomach or intestinal surgery or resection).

Note: Appendectomy and hernia repairs are allowed.

  1. The volunteer had a illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose.
  1. The volunteer has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or at Day -1 check-in (baseline).
  1. The volunteer has systolic blood pressure >140 mmHg or a diastolic blood pressure >90 mmHg.
  1. The volunteer has a clinically significant abnormality, including a marked baseline prolongation of /QTc interval (eg, repeated demonstration of a QTcF interval >450 msec), or had a family history of prolonged QTc syndrome or sudden death.
  1. The volunteer has a history of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or volunteer's verbal report and confirmed by cotinine test at check-in for each treatment period.
  1. The volunteer has a history of drug or alcohol misuse within 6 months prior to screening or a positive urine drug test at screening or at check-in for each treatment period.
  1. The volunteer has been diagnosed with acquired immune deficiency syndrome or has performed tests that are positive for (HIV), virus (HBV), or virus (HCV).
  1. The volunteer has participated in a clinical trial of another study drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the volunteer is currently enrolled in another clinical trial.
  1. The volunteer has consumed grapefruit, starfruit, Seville oranges, or their products within 7 days prior to the first dose.
  1. The volunteer has consumed herbal preparations/medications, including, but not limited to, St. John's Wort, kava, ephedra (ma huang), Ginkgo biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng, within 7 days prior to the first dose (21 days for St. John's Wort).
  1. The volunteer has experienced a weight loss or gain of >10% within 4 weeks prior to the first dose as noted by medical history and weight at screening and check-in.
  1. The volunteer has received blood or blood products within 4 weeks, donated blood or blood products within 8 weeks prior to the first dose or donated double red cell within 16 weeks prior to first dose.
  1. The volunteer has used any over-the-counter (OTC) medications or prescription drugs (including medications that can lower gastric acid, inhibit or induce P-gp and/or ) within 5 half-lives of these drugs or 2 weeks prior to the first dose of study drug, whichever is longer.
  1. The volunteer is allergic to any of the study drugs (or its ) to be given in this study.
  1. A female participant is pregnant, lactating, or breastfeeding.
  1. A male volunteer who plans to donate sperm or father a child within 30 days after receiving the study drug.
  1. The volunteer has any condition that would make him or her, in the opinion of the PI or Sponsor, unsuitable for the study, or who, in the opinion of the PI, is not likely to complete the study for any reason.

Note: One repeat of laboratory assessments may be performed at screening and at Check-In (Day -1) at the discretion of the investigator.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Part A - Itraconazole

    HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 400 mg (combination of 2 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 10) in Part A. Itraconazole will be supplied as 100 mg capsules and will be administered as doses of 200 mg (2 × 100 mg) PO BID on Day 6 and 200 mg PO QD on Days 7 to 14 in Part A.

    Drug: HMPL-523 · Drug: Itraconazole

  • Experimental
    Part B - Rifampin

    HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 700 mg (combination of 4 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 13) in Part B. Rifampin will be supplied as 300 mg capsules and will be administered as doses of 600 mg (2 × 300 mg) PO QD on Days 6 to 17 in Part B.

    Drug: HMPL-523 · Drug: Rifampin

Interventions

  • HMPL-523 is a selective small-molecule SYK inhibitor.

  • Itraconazole is an FDA approved synthetic triazole antifungal agent

  • Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state

07

What researchers measure

Primary outcomes

  1. PK parameter for HMPL-523: AUC0-t

    Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration

    Time frame: Day 1 to 18

  2. PK parameter for HMPL-523: AUC0-inf

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity (if data permit)

    Time frame: Day 1 to 18

  3. PK parameter for HMPL-523: Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to 18

Secondary outcomes

  1. Incidence of Adverse Events/ Serious Adverse Events

    Any untoward medical occurrence associated with the study drug

    Time frame: Day 1 to Day 18

08

Study locations

1 site
  • PPD Austin
    Austin, Texas 78744, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Feb 2023, 3 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 3 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 9, 2023
StartActual
Nov 4, 2022
Primary completionActual
Feb 5, 2023
CompletionActual
Feb 5, 2023
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05720767
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Nov 4, 2022
Primary completion
Feb 5, 2023
Completion
Feb 5, 2023
Last update
Mar 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion